QLS31905

DRUG5 trials

Sponsors

Qilu Pharmaceutical Co., Ltd.

Conditions

Advanced Solid TumorAdvanced Solid TumorsGastric or Gastroesophageal Junction AdenocarcinomaPancreatic CancerSolid Tumor

Phase 1

A Study of QLS31905 in Patients With Advanced Solid Tumors

Qilu Pharmaceutical Co., Ltd.Advanced Solid Tumors

Start: 2021-10-25End: 2023-12-31Target: 104Updated: 2022-03-14

A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors

Qilu Pharmaceutical Co., Ltd.Solid Tumor

Start: 2023-10-31End: 2025-10-31Target: 115Updated: 2023-09-18

Phase 2

Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

Not yet recruitingNCT06446388

Qilu Pharmaceutical Co., Ltd.Advanced Solid Tumor

Start: 2024-06-30End: 2027-12-01Target: 360Updated: 2024-06-06

Phase 3

A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer

RecruitingNCT07079228

Qilu Pharmaceutical Co., Ltd.Pancreatic Cancer

Start: 2025-09-08End: 2030-09-30Target: 602Updated: 2025-09-23

QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ

Not yet recruitingNCT07716449

Qilu Pharmaceutical Co., Ltd.Gastric or Gastroesophageal Junction Adenocarcinoma

Start: 2026-08-01End: 2029-08-01Target: 560Updated: 2026-07-21

Related Papers

First-line treatment of QLS31905 plus chemotherapy in patients with pancreatic cancer and gastric cancer: Data from a phase 1b/2 study.

Journal of Clinical Oncology2026-05-27

Safety and efficacy of QLS31905 in patients with advanced solid tumors: Updated data from phase 1 study.

Journal of Clinical Oncology2025-05-282 citations

132P A phase I clinical trial of QLS31905 in advanced solid tumors

Immuno-Oncology Technology2023-12-016 citations